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ABSTRACT:   Introduction: Up to 300 million people have the body mass index (BMI) greater than 30 kg/m2. Obesity is the cause of many se-
rious diseases, such as type 2 diabetes, hypertension, and non-alcoholic fatty liver disease (NAFLD). Bariatric surgery is the only 
effective method of achieving weight loss in patients with morbid obesity.
  Objectives: The aim of the study was to assess the impact of bariatric surgery on non-alcoholic fatty liver disease in patients op-
erated on due to morbid obesity.
  Material and Methods: We included 20 patients who were qualified for bariatric procedures based on BMI > 40 kg/m2 or BMI > 
35kg/m2 with the presence of comorbidities. The average body weight in the group was 143.85kg, with an average BMI of 49.16kg/
m2. Before the procedure, we evaluated the severity of non-alcoholic fatty liver disease in each patient using the Sheriff-Saadeh ul-
trasound scale. We also evaluated the levels of liver enzymes. Follow-up evaluation was performed twelve months after surgery.
  Results: Twelve months after surgery, the average weight was 102.34 kg. The mean %WL was 33.01%, %EWL was 58.8%, and 
%EBMIL was 61.37%. All patients showed remission of fatty liver disease. Liver damage, evaluated with ultrasound imaging, de-
creased from an average of 1.85 on the Sheriff-Saadeh scale, before surgery, to 0.15 twelve months after surgery (p < 0.001). As 
regards liver enzymes, the level of alanine aminotransferase decreased from 64.5 (U/l) to 27.95 (U/l) (p < 0.001), and the level of 
aspartate aminotransferase decreased from 54.4 (U/l) to 27.2 (U/l).
  Conclusions: Bariatric procedures not only lead to a significant and lasting weight loss, but they also contribute to the reduction 
of fatty liver disease and improve liver function.
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INTRODUCTION
Worldwide, it is estimated that there are approximately 1 billion 
overweight people, and more than 300 million suffer from obesity 
(BMI > 30kg/m2) [1]. Adipose tissue is a highly active metabolic and 
endocrine organ that contributes to the development of diabetes, 
metabolic syndrome, non-alcoholic fatty liver disease (NAFLD), 
and other conditions.
NAFLD is a broad term that encompasses many different disorders 
that range from fatty liver disease to inflammatory disease with 
fibrosis and cirrhosis. In NAFLD, the etiology of liver changes is 
not associated with alcohol consumption, despite a similar appear-
ance to alcoholic liver disease. It is hypothesized that the disease is 
possibly related to lifestyle and genetic factors. [2] The disease was 
first diagnosed in the 1930s, described in 1950s, and characterized 
histopathologically in 1980s. However, only now has it been rec-
ognized as an important clinical problem. [3] NAFLD is charac-
terized by lipid accumulation in the hepatocytes, and in NAFLD, 
lipids comprise more than 5% of the liver. NAFLD is believed to 
result from an increased flow of free fatty acids (FFA) through the 
liver. It may be caused by increased lipolysis, increased fat intake, 
mitochondrial dysfunction associated with insulin resistance, or 
by de novo lipogenesis. [7]
NAFLD is considered to be one of the main causes of chronic liver 
dysfunction in the developed world, afflicting 9–30% of the gen-
eral population. There is a well-established association between 
NAFLD and excessive caloric intake that leads to obesity. Corre-
lation between the severity of obesity and the degree of NAFLD is 
found in 90% of biopsies performed during bariatric procedures. [4]
Currently, there are no unequivocal guidelines regarding the treat-
ment of NAFLD. Weight loss, achieved through lifestyle changes 
and exercise, offers some improvement. In patients with morbid 
obesity, if these methods are ineffective, bariatric surgery seems to 
be the most appropriate treatment. Even though weight loss is the 
most visible effect of bariatric surgery, its most important goal is 
the treatment of life-threatening comorbidities. The influence of 
surgical procedures on NAFLD is poorly documented compared 
to other comorbidities, like diabetes or hypertension.
AIM OF THE STUDY
To estimate the influence of bariatric procedures on the natural 
course of non-alcoholic fatty liver disease.
MATERIAL AND METHODS
As regards the indications for surgical treatment, we used the rec-
ommendations of the Section of Metabolic and Bariatric Surgery of 
the Polish Surgeon Society, as follows, body mass index (BMI) ≥ 35 
kg/m2 with comorbidities or BMI ≥ 40 kg/m2 with or without comor-
bidities. The inclusion criteria were as follows, informed consent to 
participate in the study, age between 18-65 years, and fulfilment of 
eligibility criteria for bariatric treatment [laparoscopic sleeve gas-
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cedure was 36.42kg/m2 (down from 49.16kg/m2). The mean body 
mass was 102.34 kg (down from 143.85kg). The %WL was 33.01%, 
%EWL was 58.8%, and %EBMIL was 61.37%.
Out of all 20 patients, 14 (70%) had diabetes, and 2 (10%) had im-
paired glucose tolerance. Four patients required insulin adminis-
tration, while the remaining patients took oral anti-diabetic drugs. 
Seventeen patients (85%) were diagnosed with hypertension, and 
17 patients (85) also had hyperlipidemia. None of patients had 
obstructive sleep apnea.
In terms of concomitant diseases, we observed an improvement in 
diabetes control. Of all patients who were initially treated with an-
ti-diabetic medications, 16 (80%) went into remission and did not re-
quire further diabetic treatment. Three patients continued to require 
insulin injections; however, their daily insulin intake dropped from a 
mean of 102.0 units per day to 37.6. units per day. We achieved nor-
malization of blood pressure in 4 patients. Thirteen patients (65%) 
continued to require antihypertensive drugs. Ten patients (50%) had 
normalization of the lipid profile one year after bariatric surgery. 
Before surgery, the mean Sheriff-Saadeh score in patients under-
going the procedure was 1.85 ± 1.08. One year after surgery, the 
mean score on the Sheriff-Saadeh scale dropped to 0.15, which 
was statistically significant (p < 0.001).
The mean AST level was 60.8 ± 36.5 U/l, and the average ALT lev-
el was 49.05 ± 47.6 U/l. We observed a statistically significant re-
duction in both ALT and AST levels to 27.7U/l for ALT (p = 0.00), 
and 54.4 U/l for AST (p = 0.02).
DISCUSSION
Over the past years, surgery has gained acceptance as a treatment 
method for morbid obesity. It leads to body weight reduction to 
an extent that is unobtainable with dietary modifications alone. 
It has been proven that both laparoscopic sleeve gastrectomy and 
laparoscopic Roux-en-Y gastric bypass surgery are both efficient 
and safe.[6] 
NAFLD is a disease that is very strongly associated with obesity.
[21, 22] The Dallas Heart Study also suggests that the prevalence 
of NAFLD varies with the ethnicity. In that study, NAFLD was di-
agnosed in 45% of Latinos, 33% of Caucasians, and 24% of African 
Americans. [8] Among patients with NAFLD, 10–20% suffer from 
non-alcoholic steatohepatitis (NASH), and 8–26% of patients with 
NASH develop liver cirrhosis. [9] It has been proven that some 
genetic defects related to VLDL synthesis may have an influence 
on morbidity. [10] There are several conditions that may contrib-
ute to the development of this disease, e.g., type 2 diabetes, met-
abolic syndrome, obesity, dyslipidemia, hypogonadism, hypothy-
roidism, polycystic ovarian syndrome, and even specific bacterial 
flora in the intestine [11].
 In order to diagnose NAFLD, a history of alcohol use must be 
ruled out, along with other chronic disorders that may lead to 
chronic liver disease. In the course of the disease, elevated liver 
function tests (LFT) and a decreased level of adiponectin in pe-
ripheral blood may be observed. Other tests that may be useful in 
diagnosing NAFLD include ultrasound (US),  magnetic resonance 
trectomy (LSG) or laparoscopic Roux-en-Y gastric bypass (LRYGB)]. 
We excluded patients who were lost to follow-up after 12 months, 
patients diagnosed with mental diseases, patients diagnosed with 
alcohol or drug dependence, and patients who had undergone dif-
ferent bariatric procedures. In total, 20 patients were included in 
the study. All patients underwent laparoscopic bariatric procedures 
in the 2nd Department of General Surgery, Jagiellonian University 
Medical College. Among the patients, there were 12 women (60%) 
and 8 men (40%). The mean age was 39.55 years. The mean body 
mass was 143.85kg, and the mean BMI was 49.16kg/m2. Sixteen 
patients had either diabetes or glucose tolerance impairment. Cur-
rently, there are guidelines regarding the choice of surgery method 
is patients with diabetes, and it is believed that LRYGB is more ef-
fective in patients with a long history of diabetes. Five patients un-
derwent LSG, and 15 patients underwent LRYGB.
All patients included in this study underwent an evaluation of liv-
er function and structure in order to document the presence and 
severity of NAFLD. In order to assess liver function impairment, 
a standard set of blood liver enzymes was assessed,  including as-
partate aminotransferase (AST) and alanine aminotransferase 
(ALT). In order to evaluate liver structure and its impairment in 
the course of NAFLD, we performed ultrasound examinations. The 
Sheriff-Saadeh scale was used to assess the severity of steatohep-
atitis. The details of the Sheriff-Saadeh scale are shown in Table 
1. [5] All ultrasonographic examinations were performed by the 
same experienced physician. The General Electric LOGIQ 7 system 
with a 3.5–5.5MHz convex probe was used for all examinations.
Follow-up evaluations were performed one year after surgery. 
During follow-up visits, we evaluated the effectiveness of bariatric 
procedures in terms of weight loss and reduction of comorbidities. 
A detailed medical history was taken, and physical examinations 
were conducted. Body weight was determined using the Tanita 
BC-420S MA device. The percentage weight loss (%WL), the per-
centage loss of excessive weight (%EWL), and the percentage loss 
of excessive BMI (%EBMIL) were used to evaluate the reduction in 
body mass. To evaluate NAFLD regression, follow-up ultrasound 
examinations were performed by the same person, according to 
the Sheriff-Saadeh scale, and the same laboratory tests as before 
surgery, including AST and ALT levels, were carried out The pa-
tients were referred for psychological or dietary advice, if  they 
reported any problems in those areas. 
The Statistica 10 software was used for statistical analysis, and the 
Student’s t-test was used to the differences in AST and ALT levels 
before surgery and on follow-up. The Wilcoxon signed-rank test 
was performed for the Sheriff-Saadeh scale evaluation.
All procedures performed in studies involving human participants 
were in accordance with the ethical standards of the institutional and 
national research committee and with the 1964 Helsinki declaration 
and its later amendments or comparable ethical standards. The study 
was approved by the Bioethics Committee of the Jagiellonian Universi-
ty. The study was registered under NCT02828579 (ClinicalTrials.gov)
RESULTS
We observed a reduction in the body mass index in all patients 
who underwent surgery. The mean BMI one year after the pro-
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NAFLD may be found in up to 98% of patients undergoing bar-
iatric surgery. However, it is not associated with a higher risk of 
perioperative morbidity, even if the patient suffers from non-al-
coholic steatohepatitis (NASH), which is an advanced phase of 
NAFLD that is defined by the presence of inflammatory infiltra-
tion in the liver tissue.
Our study suggests that bariatric surgery promotes regression of 
hepatic steatosis. We observed significant improvement not only in 
liver function tests but also in Sheriff-Saadeh scores that dropped 
significantly, proportionally to the reduction in BMI. Our findings 
are similar to those from other trials that have evaluated NAFLD 
status after bariatric surgery. Vargas et al. revealed that the Roux-
en-Y gastric by-pass not only leads to body weight reduction but 
also improves liver function through regression of liver steatosis. 
[18] Hady et al., who investigated the influence of laparoscopic 
sleeve gastrectomy on the metabolic status of patients, proved 
that it causes changes in the levels of AST and ALT; however, 
these changes were not statistically significant. Nevertheless, the 
surgery was associated with a significant decline in lipid levels. 
Haafez et al. compared vertical band gastroplasty and adjustable 
gastric banding in terms of forward regression of liver steatosis in 
patients who underwent bariatric surgery. [19] Moreover, accord-
ing to Weingarten et al., NAFLD and NASH are not contraindi-
cations to bariatric surgery and do not increase the perioperative 
complication rate. [20] A limitation of our study is a small study 
sample; however, this is one of few available studies in the Europe-
an population and the first study in the Polish population. More-
over, to out knowledge, this is the only study that has investigated 
the feasibility of ultrasound scales as the sole diagnostic method 
without the need of liver biopsy. 
CONCLUSIONS
Lifestyle modification should be the first-line treatment in NAFLD; 
however, bariatric surgery should be considered as a treatment op-
tion in patients with severe and complex obesity.
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imaging (MRI), computed tomography (CT) of the abdomen, and 
liver elastography. With respect to ultrasound, low cost, safety, and 
lack of radiation exposure make it the first-line method for the di-
agnosis and follow-up of NAFLD. 
Liver biopsy remains the gold standard in the diagnosis of NAFLD. 
[12] It is the most conclusive method that can be used to exclude 
steatohepatitis, which is a condition that can lead to liver fibrosis 
and eventually cirrhosis. However, the procedure is invasive and 
carries a risk of complications, which may affect up to 20% of pa-
tients. [13] The rising incidence of NAFLD in Western countries 
underscores the necessity of developing a less invasive diagnostic 
test for distinguishing NAFLD from steatohepatitis. The use of liver 
elastography allows for the evaluation of increased liver stiffness 
in hepatic fibrosis. [14] This technique is very difficult to apply in 
bariatric patients, since in patients with a BMI greater than 28kg/
m2, there is a high possibility of misdiagnosis. [15] According to 
the authors, liver biopsy can be avoided in 75% of patients.
There are several ultrasound scales to assess the severity of NAFLD. 
The ultrasonographic scale developed by Sheriff and Saadeh is an 
easy tool for detecting and monitoring the disease. However, this 
scale, by itself, does not distinguish between steatosis and steato-
hepatitis. Nevertheless, we are convinced that this simple tool is 
very useful in the monitoring of liver status and indicating which 
patients should undergo liver biopsy.
There is strong evidence that the most effective way to diminish 
liver steatosis is body mass reduction. Promrat et al., who stud-
ied lifestyle modification as a treatment option, have shown that 
a minimum body weight loss of 7% causes improvement in liver 
histology. Dietary modification, together with physical activity, 
improves lipid levels and aminotransferases and mitigates insu-
lin resistance. [16] Research on the pharmacological treatment 
of NAFLD also offers some hope. A few drugs seem to be poten-
tially useful, including metformin, alpha-tocopherol, vitamin C, 
and thiazolidinediones. However, none of these agents has been 
proven effective in decreasing the level of liver steatosis. [16] Sur-
prisingly, regular consumption of coffee provides some protection 
against liver fibrosis. [17] Although lifestyle modification should 
be the treatment of choice in all cases of NAFLD, it is not a practi-
cal solution in patients with morbid obesity. The long-term results 
of conservative treatment of obesity and related comorbidities in 
this study group are very disappointing. So far, surgery is the only 
method that has well-documented and lasting results.
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